Historical Valuation
Medirom Healthcare Technologies Inc (MRM) is now in the Fair zone, suggesting that its current forward PS ratio of 0.27 is considered Fairly compared with the five-year average of 0.00. The fair price of Medirom Healthcare Technologies Inc (MRM) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：1.89
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Medirom Healthcare Technologies Inc (MRM) has a current Price-to-Book (P/B) ratio of 10.01. Compared to its 3-year average P/B ratio of 0.67 , the current P/B ratio is approximately 1385.11% higher. Relative to its 5-year average P/B ratio of -3.17, the current P/B ratio is about -415.79% higher. Medirom Healthcare Technologies Inc (MRM) has a Forward Free Cash Flow (FCF) yield of approximately -39.80%. Compared to its 3-year average FCF yield of -46.30%, the current FCF yield is approximately -14.03% lower. Relative to its 5-year average FCF yield of -32.93% , the current FCF yield is about 20.88% lower.
P/B
Median3y
0.67
Median5y
-3.17
FCF Yield
Median3y
-46.30
Median5y
-32.93
Competitors Valuation Multiple
AI Analysis for MRM
The average P/S ratio for MRM competitors is 0.50, providing a benchmark for relative valuation. Medirom Healthcare Technologies Inc Corp (MRM.O) exhibits a P/S ratio of 0.27, which is -46.18% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for MRM
1Y
3Y
5Y
Market capitalization of MRM increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of MRM in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is MRM currently overvalued or undervalued?
Medirom Healthcare Technologies Inc (MRM) is now in the Fair zone, suggesting that its current forward PS ratio of 0.27 is considered Fairly compared with the five-year average of 0.00. The fair price of Medirom Healthcare Technologies Inc (MRM) is between to according to relative valuation methord.
What is Medirom Healthcare Technologies Inc (MRM) fair value?
MRM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Medirom Healthcare Technologies Inc (MRM) is between to according to relative valuation methord.
How does MRM's valuation metrics compare to the industry average?
The average P/S ratio for MRM's competitors is 0.50, providing a benchmark for relative valuation. Medirom Healthcare Technologies Inc Corp (MRM) exhibits a P/S ratio of 0.27, which is -46.18% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Medirom Healthcare Technologies Inc (MRM) as of Jan 11 2026?
As of Jan 11 2026, Medirom Healthcare Technologies Inc (MRM) has a P/B ratio of 10.01. This indicates that the market values MRM at 10.01 times its book value.
What is the current FCF Yield for Medirom Healthcare Technologies Inc (MRM) as of Jan 11 2026?
As of Jan 11 2026, Medirom Healthcare Technologies Inc (MRM) has a FCF Yield of -39.80%. This means that for every dollar of Medirom Healthcare Technologies Inc’s market capitalization, the company generates -39.80 cents in free cash flow.
What is the current Forward P/E ratio for Medirom Healthcare Technologies Inc (MRM) as of Jan 11 2026?
As of Jan 11 2026, Medirom Healthcare Technologies Inc (MRM) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of Medirom Healthcare Technologies Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Medirom Healthcare Technologies Inc (MRM) as of Jan 11 2026?
As of Jan 11 2026, Medirom Healthcare Technologies Inc (MRM) has a Forward P/S ratio of 0.27. This means the market is valuing MRM at $0.27 for every dollar of expected revenue over the next 12 months.